What's Happening?
KalVista Pharmaceuticals is set to present new data on its drug EKTERLY (sebetralstat) at the 2026 Global Angioedema Leadership Conference. The company will showcase five abstracts, including a late-breaking submission, focusing on the treatment of hereditary
angioedema (HAE) in children. The presentations will highlight interim results from the KONFIDENT-KID trial, which evaluates the efficacy of sebetralstat in children aged 2-11. The conference will also feature discussions on patient satisfaction and treatment patterns for HAE attacks.
Why It's Important?
The presentation of new data on sebetralstat is significant for the treatment of hereditary angioedema, a rare genetic disorder. KalVista's research could lead to improved treatment options for children suffering from HAE, offering a non-invasive oral alternative to existing therapies. The findings may influence clinical practices and guidelines, potentially expanding the use of sebetralstat in pediatric populations. This development underscores the importance of ongoing research and innovation in addressing rare diseases and improving patient outcomes.
